Sensitivity to combined MEK and mTORC1/2 inhibition in colorectal cancer is dictated by p53 mutational status Meeting Abstract

  

Authors:	Garcia-Garcia, C.; Rivas, M. A.; Ibrahim, Y. H.; Calvo, M. T.; Grueso, J.; Antón, P.; Aura, C.; Jessen, K.; Palmer, H.; Tabernero, J.; Scaltriti, M.; Baselga, J.; Serra, V.
Abstract Title:	Sensitivity to combined MEK and mTORC1/2 inhibition in colorectal cancer is dictated by p53 mutational status
Meeting Title:	104th Annual Meeting of the American Association for Cancer Research (AACR)
Journal Title:	Cancer Research
Volume:	73
Issue:	8 Suppl.
Meeting Dates:	2013 Apr 6-10
Meeting Location:	Washington, DC
ISSN:	0008-5472
Publisher:	American Association for Cancer Research
Date Published:	2013-04-15
Language:	English
ACCESSION:	WOS:000331220601342
DOI:	10.1158/1538-7445.am2013-lb-96
PROVIDER:	wos
Notes:	Meeting Abstract: LB-96 -- 104th Annual Meeting of the American-Association-for-Cancer-Research (AACR) -- APR 06-10, 2013 -- Washington, DC -- 1 -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/52389